Newsroom
Nasdaq News Roundup: AxiomSL Revenue Change, Inducement Grants, Registered Direct Offering, and Stock Performance
By KlickAnalytics Data Insights | September 5, 2024 08:07PM ET
Key Points
- Nasdaq to discuss accounting treatment change for AxiomSL revenues
- Arcutis Biotherapeutics approves inducement grants for new employees
- Eastside Distilling announces $0.4 million registered direct offering
- Nasdaq stock sees a 42.5% rally in a year
- Adverum Biotechnologies grants stock options and RSUs under Nasdaq rules
Nasdaq, Inc. has organized a teach-in session to address the modification in revenue recognition for AxiomSL on-premises subscription contracts. This adjustment, which was mentioned during Nasdaq's second quarter earnings announcement, will have financial effects consistent with previous disclosures.
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, recently granted 37,000 restricted stock units of the company's common stock to three newly hired employees. These awards, approved by the Compensation Committee, were issued under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).
Eastside Distilling, known for its craft-inspired experiential brands, disclosed a registered direct offering totaling $0.4 million. This offering involved the sale and issuance of 442,042 shares of the company's common stock to a single institutional investor at a unit purchase price of $1.00, following Nasdaq rules.
The stock of Nasdaq has experienced a significant 42.5% rise over the past year. This increase is attributed to the company's strong organic growth, strategic acquisitions to tap into expanding market opportunities, and effective capital deployment strategies.
Adverum Biotechnologies granted inducement awards to three new employees, including non-qualified stock options and restricted stock units (RSUs). These awards were approved by the Compensation Committee under the company's 2017 Inducement Plan in adherence to Nasdaq Listing Rule 5635(c)(4).
In addition to these announcements, RedHill Biopharma has regained compliance with Nasdaq's minimum bid price requirement. Meanwhile, the S&P 500 and Nasdaq experienced a second consecutive decline, with the CNN Money Fear and Greed index indicating a "Neutral" market sentiment.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with